However, genetically determined interindividual variability in VPA pharmacokinetics associated with allelic variants in the CYP genes may vary among different ethnic and racial groups of patients with neurological diseases and mental disorders [1,23,24,25]. This evidence concerns the gene PPIG and mental disorder.